Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

6 Apr 2021

Abstract excerpt

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apoptosis across diverse blood cancers, irrespective of TP53 mutation status. Indeed, targeting BCL-2 has produced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cell death mechanisms and regulation
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33824975
DOI: 10.1182/blood.2020010167

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemiasPMID 33824975Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsSemantic proximity Read ↗

BCL2 and MCL1 inhibitors for hematologic malignanciesSemantic proximity Read ↗

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugsSemantic proximity Read ↗

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.Semantic proximity Read ↗

The rise of apoptosis: targeting apoptosis in hematologic malignanciesSemantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicineSemantic proximity Read ↗

The BCL-2 arbiters of apoptosis and their growing role as cancer targetsSemantic proximity Read ↗

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockadeSemantic proximity Read ↗

Mitochondrial apoptosis and BH3 mimeticsSemantic proximity Read ↗

Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.